1LLY Stock Overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. More details

1LLY fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	4/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 31.7% below our estimate of its fair value

Earnings are forecast to grow 22.53% per year

Earnings grew by 80.9% over the past year

Risk Analysis

High level of non-cash earnings

Has a high level of debt

Volatile share price over the past 3 months compared to the Italian market

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Eli Lilly and Company Competitors

Recordati Industria Chimica e Farmaceutica

BIT:REC

€10.9b

Novo Nordisk

CPSE:NOVO B

DKK 2.0t

Johnson & Johnson

NYSE:JNJ

US$375.6b

AstraZeneca

LSE:AZN

UK£166.8b

Price History & Performance

Summary of share price highs, lows and changes for Eli Lilly
Historical stock prices
Current Share Price	US$724.20
52 Week High	US$883.20
52 Week Low	US$609.40
Beta	0.50
1 Month Change	5.77%
3 Month Change	-7.36%
1 Year Change	3.68%
3 Year Change	164.11%
5 Year Change	396.03%
Change since IPO	589.71%

Recent updates

Shareholder Returns

	1LLY	IT Pharmaceuticals	IT Market
7D	-5.2%	4.9%	2.5%
1Y	3.7%	-12.3%	12.1%

Return vs Industry: 1LLY exceeded the Italian Pharmaceuticals industry which returned -12.3% over the past year.

Return vs Market: 1LLY underperformed the Italian Market which returned 12.1% over the past year.

Price Volatility

Is 1LLY's price volatile compared to industry and market?
1LLY volatility
1LLY Average Weekly Movement	7.1%
Pharmaceuticals Industry Average Movement	5.9%
Market Average Movement	5.3%
10% most volatile stocks in IT Market	8.8%
10% least volatile stocks in IT Market	3.3%

Stable Share Price: 1LLY's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: 1LLY's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Italian stocks.

About the Company

Founded	Employees	CEO	Website
1876	47,000	Dave Ricks	www.lilly.com

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.

Eli Lilly and Company Fundamentals Summary

How do Eli Lilly's earnings and revenue compare to its market cap?
1LLY fundamental statistics
Market cap	€653.99b
Earnings (TTM)	€9.82b
Revenue (TTM)	€43.34b

66.6x

P/E Ratio

15.1x

P/S Ratio

Is 1LLY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1LLY income statement (TTM)
Revenue	US$49.00b
Cost of Revenue	US$8.97b
Gross Profit	US$40.03b
Other Expenses	US$28.93b
Earnings	US$11.11b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Aug 07, 2025

Earnings per share (EPS)	12.37
Gross Margin	81.70%
Net Profit Margin	22.66%
Debt/Equity Ratio	243.6%

How did 1LLY perform over the long term?

See historical performance and comparison

Dividends

0.7%

Current Dividend Yield

44%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/05 05:21
End of Day Share Price	2025/05/02 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eli Lilly and Company is covered by 57 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Ishan Majumdar	Baptista Research
Luisa Hector	Berenberg